Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

The non-receptor tyrosine kinase Src activation plays a role in the malignant progression of breast cancer, including development of endocrine therapy resistance and survival of bone metastases. This study investigated whether adding Src kinase inhibitor dasatinib to aromatase inhibitor (AI) therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Devchand, Vukelja, Svetislava J., Ann Holmes, Frankie, Blum, Joanne L., McIntyre, Kristi J., Lindquist, Deborah L., Osborne, Cynthia R., Sanchez, Ines J., Goldschmidt, Jerome H., Wang, Yunfei, Asmar, Lina, Strauss, Lewis, O’Shaughnessy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817898/
https://www.ncbi.nlm.nih.gov/pubmed/31667338
http://dx.doi.org/10.1038/s41523-019-0132-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817898/
https://www.ncbi.nlm.nih.gov/pubmed/31667338
http://dx.doi.org/10.1038/s41523-019-0132-8

Ejemplares similares